Open an account

Harvard Apparatus Regenerative Technology

HRGN · OTC

$2.20−$0.014 (−0.63%)TodayMarket closed ·
Prev close $2.21

About HRGN

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. The company is headquartered in Holliston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2013-10-14. The firm's technology is based on its cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. The firm is advancing its Cellspan esophageal implant product candidate through an Investigator-Initiated Trial targeting pediatric patients with Esophageal Atresia. Its biocompatible scaffold component of its esophageal implant is constructed primarily of thin polyurethane fibers. Its other product candidates in development pipeline are targeted at the reconstruction of the colon and uterus wound repair. The Company, through its subsidiary, Harvard Apparatus Regenerative Technology Limited, is focused on personal healthcare, including dietary supplements.

Employees
8
Headquarters
Holliston, Massachusetts
Listed
Oct 14, 2013
Sector
Health Care
Industry
Biotechnology
Website
hregen.com

HRGN key statistics

Market cap
44.63M
Price-earnings ratio
-6.95
Dividend yield
—
Average volume
1.87K
Volume
1.10K
Open price
$2.16
High today
$2.20
Low today
$2.16
52 Week high
$2.46
52 Week low
$0.96

Harvard Apparatus Regenerative Technology (HRGN) at a glance

Harvard Apparatus Regenerative Technology (HRGN) last traded at $2.20, with a market cap of 44.63M and a price-to-earnings ratio of -6.95.

Today the stock has traded between $2.16 and $2.20. The current price is 1.8% above the day's low and 0.0% below its high.

Volume so far is 1.10K shares, below the average of 1.87K shares a day.

Over the past year Harvard Apparatus Regenerative Technology has ranged from $0.96 to $2.46, and now sits 83% of the way up that range.

Harvard Apparatus Regenerative Technology met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY25 it reported -$0.11 per share against an estimate of $0.00.

HRGN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 25.5% on average.

  1. Q3 FY16: reported -$3.60 per share against an estimate of -$5.10
  2. Q4 FY16: reported -$4.00 per share against an estimate of -$4.28
  3. Q1 FY17: reported -$2.80 per share against an estimate of -$4.69
  4. Q2 FY17: reported -$2.00 per share against an estimate of -$1.43
  5. Q3 FY23: reported -$0.12 per share against an estimate of $0.00
  6. Q4 FY23: reported -$0.13 per share against an estimate of $0.00
  7. Q2 FY24: reported -$0.18 per share against an estimate of $0.00
  8. Q2 FY25: reported -$0.11 per share against an estimate of $0.00

Similar companies

Companies in the same industry as Harvard Apparatus Regenerative Technology

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.